Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
Business Wire India Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response…